failed_experiment.db
← Back to browse

Medicine› Ophthalmology› Retinal Diseases and Treatments

Age-related macular degeneration — Vaccinia virus complement control protein (VCP)

Submitted 2026-10-23

Field: Medicine › OphthalmologyType: An approach that didn't workArea: age-related macular degenerationTarget: Vaccinia virus complement control protein (VCP)Stage: preclinical

Hypothesis

VCP, a complement inhibitor that protects nerve tissue in brain and spinal cord injury models, would protect the rat retina from light-induced degeneration.

What failed

In light-damaged retinas, VCP did not reduce photoreceptor loss, retinal stress or inflammation compared with saline. Injected VCP spread through the retina but was cleared within 1 to 3 hours.

Broken assumption

A single eye injection of a complement inhibitor stays in the retina long enough to protect it.

Why

VCP did not stay in the retina long enough to act, so a slow-release delivery method is needed before the idea can be properly tested.

From the published paper: Fernando et al. PLoS ONE, 2018. ↗CC BY

Research ideas from this failure

Unvetted lead — read the papers

New hypotheses this failure suggests, each with a crucial experiment, a rival explanation of the original result, and the papers it rests on. Written by AI from paper titles and abstracts found on OpenAlex (and Europe PMC, for life and health sciences).

Related failures (2)

Matched on shared genes, mechanisms and ways of failing as well as wording. Each shows why it matched — treat these as leads rather than verdicts.

Links in published research

Where this experiment's genes are known to matter outside its own research area, and the papers behind those links. Sources: Open Targets Platform and Europe PMC.